Abstract: The present invention relates to a compound represented by formula (I), a tautomer thereof or a pharmaceutically acceptable salt thereof, and relates to applications thereof in the preparation of drugs for treating FXR related diseases.
Type:
Grant
Filed:
January 25, 2017
Date of Patent:
December 29, 2020
Assignee:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Abstract: Disclosed are a crystal of a maleate of a compound of formula (I), a preparation method for the crystal, a crystallization composition of same, a pharmaceutical composition of same, and uses thereof in preventing and treating a tumor.
Type:
Grant
Filed:
August 24, 2017
Date of Patent:
December 8, 2020
Assignees:
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO. LTD., LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD., CENTAURUS BIOPHARMA CO., LTD.
Inventors:
Song Tang, Yizhong Zhu, Fei Liu, Jie Zhou, Zhilin Chen, Hongjiang Xu, Xin Tian
Abstract: Provided are a crystal and salt of an m-dihydroxybenzene derivative represented by formula (I), a manufacturing method thereof, and an application of the crystal in preparing a pharmaceutical product for treating a HSP90-mediated disease.
Type:
Grant
Filed:
July 20, 2017
Date of Patent:
December 1, 2020
Assignee:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Inventors:
Xiaobing Yan, Wei Huang, Dan Li, Charles Z. Ding, Fei Liu, Xiquan Zhang
Abstract: Provided is an amino pyrazolopyrimidine compound as represented by the following structural formula used as a neurotrophic factor tyrosine kinase receptor inhibitor. The compound can inhibit the activity of Trk kinase and can treat diseases mediated by a Trk tyrosine kinase receptor in mammals.
Type:
Grant
Filed:
October 27, 2017
Date of Patent:
November 10, 2020
Assignees:
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., CENTAURUS BIOPHARMA CO., LTD., LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD.
Abstract: The present application relates to a crystal of a compound represented by Formula (I), a salt thereof, and a crystal of the salt thereof, a method for preparing the crystal of the compound represented by Formula (I), the salt thereof, and the crystal of the salt thereof, a crystal comprising the compound represented by Formula (I), a crystal composition comprising the crystal of the salt thereof, a pharmaceutical composition thereof, and medical uses thereof.
Type:
Grant
Filed:
August 11, 2017
Date of Patent:
November 3, 2020
Assignees:
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD., CENTAURUS BIOPHARMA CO., LTD.
Abstract: The present application discloses an indole as represented by formula (I) used as a CRTH2 inhibitor, and a pharmaceutically acceptable salt or tautomer of the indole, and an application of same in treating a disease related to a CRTH2 receptor.
Type:
Grant
Filed:
July 21, 2017
Date of Patent:
October 13, 2020
Assignee:
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
Inventors:
Yuanshan Yao, Bin Chen, Yuan Chen, Ao Li, Ran Xu, Zhensheng Huang, Dongdong Tian, Hongwei Li, Chengshuai Yang, Jian Li, Shuhui Chen
Abstract: The present invention relates to a maleate salt of a compound represented by formula I, a method for preparing the salt, a pharmaceutical composition containing the salt, and the use of the salt. The present invention also relates to crystalline forms C, D and E of the maleate salt of the compound represented by formula I, methods for preparing the crystalline forms, crystalline compositions and pharmaceutical compositions containing the crystalline forms, and uses thereof.
Type:
Grant
Filed:
February 4, 2017
Date of Patent:
September 22, 2020
Assignee:
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
Abstract: The present application relates to a crystalline sulfamide compound, and in particular relates to a crystalline (S)-N-((S)-1-(2-chlorphenyl)-2-((3,3-difluorocyclobutyl)amido)-2oxoethyl)-2-(4-cyanopyridin-2-base)-N-(3-fluorophenyl)-isothiazolidine-3-formamide 1,1-dioxide, and a preparation method therefor, a crystalline composition, a pharmaceutical composition and uses thereof. An X-ray powder diffraction spectrum of a crystalline hydrate of formula II of the present application has diffraction peaks at positions of about 14.40°, 20.28°, 20.94°, 22.02°, and 24.46°, represented by 2?. The crystalline hydrate of formula II of the present application has good IDH1 inhibitory activity and performs high stability, and therefore has advantages in physical property, safety and metabolic stability, and has high medicine value.
Type:
Application
Filed:
September 21, 2018
Publication date:
September 17, 2020
Applicants:
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD., CENTAURUS BIOPHARMA CO., LTD.
Abstract: Provided are a preparation method for a chiral pyrrolopyrimidine compound and a related intermediate. In the method, a compound of formula A and a compound of formula 6 or a salt thereof are reacted to obtain a compound of formula 7 or a compound of formula 14, and a compound of formula I is prepared from the compound of formula 7 or the compound of formula 14. Also provided are the intermediate used, a preparation method for the intermediate and a use of the intermediate in the preparation of the compound of formula I. The preparation method has characteristics such as brief steps, a high stereoselectivity, a high utilization ratio of atoms, mild reaction conditions and a convenient post-treatment. The method avoids using an expensive asymmetric reaction catalyst, and is suitable for industrial production.
Type:
Grant
Filed:
June 15, 2017
Date of Patent:
September 8, 2020
Assignees:
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD., CENTAURUS BIOPHARMA CO., LTD.
Abstract: The present invention provides a silicon-containing compound for resistance to hepatitis c virus infection, and in particular provides a compound represented by formula I, or a pharmaceutically acceptable salt, or a tautomer, or a stereoisomer, or a deuterated compound thereof and mixture among them, a preparation process therefor, and a pharmaceutical composition comprising the same. The present application also provides a use of the compound, or a pharmaceutically acceptable salt, or a tautomer, or a stereoisomer, or a deuterated compound thereof and mixture among them, and a pharmaceutical composition comprising the same in treatment of hepatitis c virus infection.
Type:
Grant
Filed:
March 22, 2018
Date of Patent:
September 8, 2020
Assignee:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Abstract: Disclosed are compounds having formulae I and II or pharmaceutically acceptable salts or hydrates thereof, a preparation method thereof and pharmaceutical compositions thereof. The compounds having formulae I and II possesses an isocitrate dehydrogenase 2 (IDH2) inhibitory activity and are capable of treating IDH2 mutation-induced cancers.
Type:
Grant
Filed:
July 29, 2016
Date of Patent:
August 18, 2020
Assignees:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Lianyungang Runzhong Pharmaceutical Co., Ltd., Centaurus Biopharma Co., Ltd.
Abstract: Provided is a sulfonyl-substituted bicyclic compound (A) which acts as a ROR? inhibitor, said compound has good ROR? inhibitory activity and is expected to be used for treating diseases mediated by a ROR? receptor in mammals.
Type:
Application
Filed:
September 30, 2018
Publication date:
July 30, 2020
Applicants:
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., NANJING GEAR PHARMA & TECH CO., LTD.
Abstract: A bicyclic compound acting as a ROR? inhibitor. Provided are a compound of formula (I) or a pharmaceutically acceptable salt thereof, the compound having a structure as represented by formula (I-A) or formula (I-B). The provided compound of formula (I-A) or formula (I-B) or pharmaceutically acceptable salt thereof has good ROR? inhibitory activities, being expected to be used for treating diseases mediated by ROR? receptors in a mammal.
Type:
Application
Filed:
July 27, 2018
Publication date:
July 23, 2020
Applicants:
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., MEDSHINE DISCOVERY INC.
Inventors:
Kevin X CHEN, Kai ZHOU, Yanxin YU, Boyu HU, Linghui WU, Xiaoyuan CHEN, Jiangfeng LIN, Haomin CHEN, Xiangjian WANG, Xiquan ZHANG, Xin TIAN, Hongjiang XU
Abstract: The present invention relates to the field of pharmaceutical chemistry, and relates to a deuterium-modified Brigatinib derivative, preparation method thereof, pharmaceutical composition containing the same and the uses of the deuterium-modified Brigatinib derivative and the pharmaceutical composition thereof in preparing a medicament for treating the disease mediated by anaplastic lymphoma kinase. The deuterium-modified Brigatinib derivative of the present invention has an excellent inhibitory activity on anaplastic lymphoma kinase and has better pharmacodynamic or pharmacokinetic properties relative to Brigatinib.
Type:
Grant
Filed:
November 24, 2016
Date of Patent:
July 21, 2020
Assignee:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Inventors:
Yinsheng Zhang, Baomin Liu, Beibei Yang
Abstract: Provided are a Syk inhibitor and a use method therefor, and in particular, disclosed are quinolinone represented by formula (I) or quinazoline derivatives or pharmaceutically acceptable salts thereof, a preparation method, a pharmaceutical composition, and uses in preparing a medicament for treatment of Syk receptor related diseases.
Type:
Application
Filed:
June 14, 2018
Publication date:
June 25, 2020
Applicant:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Abstract: The present invention relates to a trifluoroacetate salt of a TLR7 agonist 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine (formula I), crystalline form B of the trifluoroacetate salt, methods for preparing the trifluoroacetate salt and crystalline form B, and uses of the trifluoroacetate salt and crystalline form B.
Type:
Grant
Filed:
February 4, 2017
Date of Patent:
June 16, 2020
Assignee:
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
Abstract: The present invention relates to a 7-(thiazol-5-yl)pyrrolopyrimidine compound as a TLR7 agonist, and particularly relates to a compound shown in formula (I), pharmaceutically acceptable salt and preparation method thereof, a pharmaceutical composition containing such a compound, and usage thereof in preparing an antiviral drug.
Type:
Grant
Filed:
November 4, 2016
Date of Patent:
June 9, 2020
Assignee:
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
Abstract: Disclosed are compounds having formulae I and II or pharmaceutically acceptable salts or hydrates thereof, a preparation method thereof and pharmaceutical compositions thereof. The compounds having formulae I and II possesses an isocitrate dehydrogenase 2 (IDH2) inhibitory activity and are capable of treating IDH2 mutation-induced cancers.
Type:
Grant
Filed:
July 29, 2016
Date of Patent:
May 19, 2020
Assignees:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Lianyungang Runzhong Pharmaceutical Co., Ltd., Centaurus Biopharma Co., Ltd.
Abstract: The present invention relates to a method for preparing a pyrrolo[3,2-d]pyrimidine compound (the compound represented by formula I), and corresponding intermediates.
Type:
Grant
Filed:
February 4, 2017
Date of Patent:
May 19, 2020
Assignee:
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.